Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
bauschhealth.com

See what CB Insights has to offer

Portfolio Exits

12

Partners & Customers

10

About Bausch Health

Bausch Health (NYSE/TSX: BHC) s a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology.

Bausch Health Headquarter Location

2150 St. Elzear Blvd. West

Laval, Quebec, H7L 4A8,

Canada

800-361-1448

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bausch Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bausch Health in 2 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

237 items

M

Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Bausch Health Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bausch Health Rank

Latest Bausch Health News

Insights on the Cosmetic Surgery and Procedures Global Market to 2028 - An Increasing Number of Men Undergoing Cosmetic Procedures Presents Opportunities

Jan 14, 2022

According to this report the global cosmetic surgery and procedures market is assessed to exhibit growth at a CAGR of 6.25% during the forecast years of 2021-2028. Factors such as technological advancements in cosmetic devices, coupled with the rising acceptance of aesthetic procedures, are driving the studied market's growth. Over the years, the surgical segment has shifted to cosmetic procedures. This is mainly owing to the advancements in technologies, such as the advent of minimally invasive aesthetic devices and laser therapies. Additionally, the rising number of men undergoing cosmetic procedures and increasing awareness pertaining to cosmetic surgery benefits are opening new avenues for the cosmetic surgery and procedures market. Regional Outlook The global cosmetic surgery and procedures market covers the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions. Geographically, the Asia-Pacific is anticipated to become the fastest-growing region in the cosmetic surgery and procedures market. This growth can be because of the high population base, increasing disposable income, and rising patient awareness about beauty. Moreover, medical tourism and technological advancements have made the region a lucrative market for medical aesthetics. Further, cosmetic surgery in countries like India has evolved significantly, influencing cosmetic procedures among consumers. Hence, all these factors are propelling the growth of the cosmetic surgery and procedures market in the APAC region. Competitive Outlook The established companies in the cosmetic surgery and procedures market are Galderma Laboratories LP, Candela Corporation, Bausch Health Companies Inc, Lumenis Ltd, Cynosure Inc, Alma Lasers Ltd, Allergan, Merz Pharma, Ipsen Group, Sinclair Pharma, Cutera Inc, Sientra Inc, and Johnson and Johnson. Johnson and Johnson is a healthcare company engaged in developing, manufacturing, and marketing consumer products, pharmaceuticals, and medical devices. It provides pharmaceuticals in the therapeutic areas, including cardiovascular, immunology, and others. It markets its products under various brands, such as Simponi, Neutrogena, Clean & Clear, and OGX, among others. Additionally, the company offers medical devices for general surgery, biosurgery, and other procedures. Johnson and Johnson have operations across the globe, with headquarters in New Jersey, the United States. Key Topics Covered: 2. Industry Outlook 2.2. Key Insights 2.2.2. R&D Activities and Regulatory Approvals for Botulinum Toxin 2.2.3. Substantial Growth in the Availability and Provision of Minimally Invasive Treatments 2.3. Porter's Five Forces Analysis 2.3.1. Threat of New Entrants 2.3.2. Threat of Substitutes 2.3.4. Bargaining Power of Suppliers 2.3.5. Threat of Competitive Rivalry 2.4. Market Attractiveness Index

Bausch Health Portfolio Exits

12 Portfolio Exits

Bausch Health has 12 portfolio exits. Their latest portfolio exit was Amoun Pharmaceutical on March 31, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/31/2021

Acquired - II

$99M

4

9/4/2019

Acquired - II

6

5/24/2018

Acquired - II

$99M

1

11/10/2017

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

11/6/2017

Acquired - II

Subscribe to see more

Subscribe to see more

10

Date

3/31/2021

9/4/2019

5/24/2018

11/10/2017

11/6/2017

Exit

Acquired - II

Acquired - II

Acquired - II

Divestiture

Acquired - II

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

6

1

10

10

Bausch Health Acquisitions

19 Acquisitions

Bausch Health acquired 19 companies. Their latest acquisition was Synergetics USA on September 02, 2015.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/2/2015

$99M

Acquired

1

8/20/2015

Convertible Note

$99M

$122.38M

Acquired

1

7/23/2015

$99M

Acquired Unit

1

7/17/2015

Subscribe to see more

$99M

Subscribe to see more

10

4/1/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/2/2015

8/20/2015

7/23/2015

7/17/2015

4/1/2015

Investment Stage

Convertible Note

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$122.38M

Note

Acquired

Acquired

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Bausch Health Partners & Customers

10 Partners and customers

Bausch Health has 10 strategic partners and customers. Bausch Health recently partnered with Anaqua on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/15/2021

Vendor

Anaqua

United States

Business : Anaqua selected to deliver enhanced IP management to Bausch Health

Anaqua selected to deliver enhanced IP management to Bausch Health Companies Inc

1

9/14/2021

Vendor

Anaqua

United States

Anaqua Delivers Enhanced IP Management to Bausch Health

Anaqua , the leading innovation and intellectual property management technology provider , announced that Bausch Health Companies Inc. has selected Anaqua 's AQX platform to deliver enhanced IP management across the health care products company 's global operations .

1

5/17/2021

Supplier

Societa Industria Farmaceutica Italiana

Italy

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

`` SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health , '' Gilberto Dalesio , SIFI 's CCO , said in a company news release .

3

5/3/2018

Licensor

Progenics Pharmaceuticals

United States

Subscribe to see more

Subscribe to see more

10

4/12/2018

Licensee

Cosmo Pharmaceuticals

Ireland

Subscribe to see more

Subscribe to see more

10

Date

9/15/2021

9/14/2021

5/17/2021

5/3/2018

4/12/2018

Type

Vendor

Vendor

Supplier

Licensor

Licensee

Business Partner

Anaqua

Anaqua

Societa Industria Farmaceutica Italiana

Progenics Pharmaceuticals

Cosmo Pharmaceuticals

Country

United States

United States

Italy

United States

Ireland

News Snippet

Business : Anaqua selected to deliver enhanced IP management to Bausch Health

Anaqua selected to deliver enhanced IP management to Bausch Health Companies Inc

Anaqua Delivers Enhanced IP Management to Bausch Health

Anaqua , the leading innovation and intellectual property management technology provider , announced that Bausch Health Companies Inc. has selected Anaqua 's AQX platform to deliver enhanced IP management across the health care products company 's global operations .

SIFI and Bausch Health Russia Announce Strategic Commercial Partnership

`` SIFI is committed to continuous development and expansion and is pleased to announce this strategic partnership with Bausch Health , '' Gilberto Dalesio , SIFI 's CCO , said in a company news release .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

3

10

10

Bausch Health Team

17 Team Members

Bausch Health has 17 team members, including current Chief Compliance Officer, Senior Vice President, Seana Carson.

Name

Work History

Title

Status

Seana Carson

Chief Compliance Officer, Senior Vice President

Current

Tim Tyson

Avara Pharmaceutical Services, Aptuit, GlaxoSmithKline, and U.S. Army

Chief Executive Officer, President

Former

Rod Unsworth

Pharmacia Corporation

Chief Executive Officer

Former

Chuck J Bramlage

President

Former

James Caggiano

President

Former

Name

Seana Carson

Tim Tyson

Rod Unsworth

Chuck J Bramlage

James Caggiano

Work History

Avara Pharmaceutical Services, Aptuit, GlaxoSmithKline, and U.S. Army

Pharmacia Corporation

Title

Chief Compliance Officer, Senior Vice President

Chief Executive Officer, President

Chief Executive Officer

President

President

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.